Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Concurrent Chemoradiotherapy and Adaptive Radiotherapy in EGFR-Positive Locally Advanced Cervical Squamous Cell Carcinoma
ChiCTR2600128056Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jul 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nimotuzumab in Cervical Cancer (CC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Objective response rate, Complete response rate and 1 more. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
nimotuzumab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2600128056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128056.